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AbstrACt
Introduction Pain negatively affects the health- related 
quality of life (HRQL) of adolescents with cancer. The 
Pain Squad+ smartphone- based application (app), has 
been developed to provide adolescents with real- time 
pain self- management support. The app uses a validated 
pain assessment and personalised pain treatment advice 
with centralised decision support via a registered nurse 
to enable real- time pain treatment in all settings. The 
algorithm informing pain treatment advice is evidence- 
based and expert- vetted. This trial will longitudinally 
evaluate the impact of Pain Squad+, with or without the 
addition of nurse support, on adolescent health and cost 
outcomes.
Methods and analysis This will be a pragmatic, 
multicentre, waitlist controlled, 3- arm parallel- group 
superiority randomised trial with 1:1:1 allocation enrolling 
74 adolescents with cancer per arm from nine cancer 
centres. Participants will be 12 to 18 years, English- 
speaking and with ≥3/10 pain. Exclusion criteria are 
significant comorbidities, end- of- life status or enrolment in 
a concurrent pain study. The primary aim is to determine 
the effect of Pain Squad+, with and without nurse support, 
on pain intensity in adolescents with cancer, when 
compared with a waitlist control group. The secondary 
aims are to determine the immediate and sustained effect 
over time of using Pain Squad+, with and without nurse 
support, as per prospective outcome measurements of 
pain interference, HRQL, pain self- efficacy and cost. Linear 
mixed models with baseline scores as a covariate will be 
used. Qualitative interviews with adolescents from all trial 
arms will be conducted and analysed.
Ethics and dissemination This trial is approved by the 
Hospital for Sick Children Research Ethics Board. Results 
will provide data to guide adolescents with cancer and 
healthcare teams in treating pain. Dissemination will 
occur through partnerships with stakeholder groups, 
scientific meetings, publications, mass media releases and 
consumer detailing.
trial registration number NCT03632343 ( ClinicalTrials. 
gov).
IntroduCtIon
Adolescents with cancer report pain as the 
most commonly occurring and distressing 
cancer- related symptom experienced.1–3 Pain 
negatively impacts health- related quality of 
life (HRQL),4–6 represents a significant cost 
burden to patients, families and the health 
system7 and is a major reason for cancer- 
related emergency health service use in adult 
patients.8–11 However, the successful identi-
fication of pain, including in and outside of 
the hospital setting, does not equate to its 
adequate treatment and pain is often under-
treated in adolescents.12–15
Due to improvements in therapeutic 
regimes, supportive care and changes in the 
health system, adolescents with cancer now 
spend less time in hospital and more time at 
home.16–18 Thus, adolescents and their fami-
lies are increasingly responsible for managing 
strengths and limitations of this study
 ► This study is a large trial evaluating an innovative 
method to address pain in adolescents with cancer, 
the most common and distressing symptom experi-
enced by this group.
 ► This pragmatic design of the trial means that our 
approach to study eligibility criteria, intervention 
intensity and participant adherence will determine 
intervention effect under real- world conditions.
 ► Former adolescent cancer patients are core mem-
bers of this study team and have, and will continue 
to, guide and support study design, study conduct 
and results dissemination.
 ► Adolescents with cancer, their caregivers and the 
study nurse will not be blinded to participant group 
as this is prohibited by the nature of the intervention.
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Figure 1 Pain Squad+ smartphone application screenshots of the application landing screen (A), a visual analogue slider scale 
for pain assessment (B) and a portion of the library of pain self- management advice. Photos used in this figure are stock photos 
and are under license from the copyright owners.
cancer- associated pain in environments with less super-
vision from healthcare professionals.13 19 Adolescents are 
more vulnerable in these environments as they often lack 
the knowledge, skills and self- efficacy needed to adequately 
react to symptoms and may ignore or inappropriately 
accept changes in pain.13 16 20 21 Digital health technologies 
are widely used by adolescents22 and can empower adoles-
cents with cancer to engage in remote and real- time pain 
treatment in all of their natural environments (eg, hospital, 
home, school). Studies have indicated that digital real- time 
symptom monitoring and treatment improves HRQL and 
decreases emergency service use and hospitalisation rates 
in adults with cancer,23 24 but no such research has been 
conducted with adolescents.
the Pain squad+ smartphone-based real-time pain treatment 
application
Using a phased- centred and user- centred approach, our 
team has developed a smartphone application (app), 
called Pain Squad+, capable of providing adolescents 
with real- time pain treatment support (figure 1).25–31 
Pain Squad+ uses a truncated 8- item version of a valid 
and reliable automated questionnaire to assess adoles-
cent pain (severity, interference, location and capacity 
to self- manage pain).12 When pain is reported using Pain 
Squad+, self- management advice is presented to users in 
real- time according to a vetted and standardised clinical 
care algorithm.25 28 Advice is based on a library of pharma-
cological (eg, medication adherence reminders), psycho-
logical (eg, distraction techniques) and physical (eg, 
yoga instruction) advice that aligns with typical recom-
mendations provided to adolescents by their healthcare 
teams.32 Three consecutive moderate- to- severe reports of 
pain intensity (ie, ≥3/10)33 trigger an email to be sent 
to a paediatric oncology- trained registered nurse. The 
nurse then contacts the adolescent and/or their health-
care team to discuss the case and initiate healthcare 
professional- driven intervention, which may be outside 
of the scope of the self- management algorithm (eg, 
adjusting a prescribed medication regime). To encourage 
engagement with Pain Squad+, the app is ‘gamified’ with 
users playing the role of superheroes who receive rewards 
for adherence to pain assessment and treatment recom-
mendation completion.19
The most recently completed phase of Pain Squad+ 
testing was a 1- group, baseline- poststudy pilot that demon-
strated the feasibility (ie, intervention fidelity, outcome 
measure completion, adherence, acceptability) of evalu-
ating the app in a randomised controlled trial (RCT), as 
well as small- to- moderate effect sizes (Cohen’s d: 0.23 to 
0.67).30 This protocol details the methods to be used in 
the next phase of Pain Squad+ testing: a RCT aimed at 
longitudinally evaluating the impact of Pain Squad+, with 
or without the addition of nurse support, on adolescent 
health and cost outcomes.
specific objectives
Primary objective and hypothesis
To examine the effect of 4 weeks of Pain Squad+ app 
use, with and without nurse support, on pain intensity 
in adolescents with cancer, when compared with a wait-
list control group. We hypothesise that 4 weeks of Pain 
Squad+ use, with or without nurse support, will result in 
improved pain intensity scores, compared with a waitlist 
control group.
Secondary objectives and hypotheses as appropriate
Objective related to the effect of Pain Squad+ on health outcomes 
overtime.
To examine the effect of each of 2, 4 and 8 weeks of 
Pain Squad+ app use, with and without nurse support, 
on each of pain intensity, pain interference, HRQL 
and pain management self- efficacy in adolescents with 
cancer, when compared with a waitlist control group. We 
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Figure 2 Flowchart of Pain Squad+ trial protocol. AWC,adolescents with cancer.
hypothesise that Pain Squad+ use, with or without nurse 
support, for 2, 4 and 8 weeks will result in improved 
pain intensity, pain interference, HRQL and self- efficacy 
scores, compared with a waitlist control group.
Objective related to maintenance of potential therapeutic gains 
from Pain Squad+ use
To examine the effect of the Pain Squad+ app, with and 
without nurse support, on each of pain intensity, pain 
interference, HRQL and pain management self- efficacy in 
adolescents with cancer compared with a waitlist control 
group, when assessed after intervention use has ceased 
(ie, 8 weeks post- use of the intervention). We hypothesise 
that improvements in pain intensity, pain interference, 
HRQL and self- efficacy scores related Pain Squad+ use, 
with or without nurse support, will be sustained when 
assessed after intervention use has ceased.
Objective related to the effect of Pain Squad+ on health system 
and societal costs.
To examine the cost- effectiveness and cost utility of 
the Pain Squad+ app, with and without nurse support as 
compared with standard care from both a health system 
and societal perspective.
Objective related to treatment arm satisfaction.
To explore adolescent with cancer- rated acceptability 
(including engagement with pain treatment strategies) of 
the Pain Squad+ app and the study following participation.
MEthods
trial design
This will be a pragmatic, multicentre, waitlist group- 
controlled, investigator and analyst- blinded, 3- arm 
parallel- group superiority RCT with 1:1:1 allocation 
(figure 2). Randomisation will be stratified by recruitment 
site to account for differences in care across centres34 with 
block sizes of 6 and 9 within each stratum. Reporting of 
this protocol is in accordance with the Standard Protocol 
Items: Recommendations for Interventional Trials 
(SPIRIT) guidelines35 (see online supplementary addi-
tional file for SPIRIT checklist).
study setting
Adolescent and caregiver recruitment will occur across 
nine Canadian paediatric oncology programmes that 
treat a diversity of paediatric cancers (often based on the 
same standardised protocols). All of these programmes 
are located in tertiary care centres that serve paediatric 
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Table 1 Pain Squad+ RCT participation eligibility criteria
Criterion Rationale Source
Inclusion criteria
12 to 18 years of age Study restricted to AWC Medical chart
Diagnosed with cancer (all disease types) 
and receiving cancer- directed therapy
Study restricted to AWC Medical chart
English- speaking and reading Pain Squad+ app currently available in 
English only
AWC self- report
Average pain score of ≥3/10 over the 
preceding week
Value describes moderate- severe pain 
in adolescents33 and RCTs of similar 
interventions in adults with cancer pain.36 37 In 
our pilot, 75% of AWC reported average pain 
of ≥3/10 in the week prior to enrolment.
AWC self- report measured using an 
11- point numerical rating scale
English- speaking and reading caregiver 
who is willing and able to complete 
outcome measures related to healthcare 
encounters
English- speaking caregivers required 
to complete outcome measure related 
healthcare utilisation and associated costs.
AWC or caregiver self- report
Exclusion criteria
Significant cognitive impairments or 
comorbid illnesses
Would limit interaction with Pain Squad+ or 
outcome measure assessment
Healthcare team report
Currently participating in other pain 
treatment studies
Concomitant intervention represents a threat 
to internal validity
AWC or caregiver self- report
Not expected to survive past 16 weeks Terminal data collection point is at 16 weeks 
post- randomisation
Healthcare team report
app, application; AWC, adolescents with cancer; RCT, randomised controlled trial.
populations with considerable racial, ethnic and socio-
economic diversity. The lead study site is the Hospital for 
Sick Children (SickKids).
Eligibility criteria
The eligibility criteria for this study, with the rationale for 
each criterion and the sources of associated data collec-
tion, are shown in table 1. No restrictions will be placed 
on analgesia use or hospitalisations, however data related 
to medication and other pain treatment strategy use, as 
well as inpatient stays (ie, reason, duration, pain- related 
treatment received), will be collected during the study.
Interventions
Experimental group A
The deployment of the Pain Squad+ app to adolescent’s 
personal phones will be done through the Apple App 
Store and Google Play Store. The research team will loan 
an iPhone or Android phone to those without a smart-
phone. All adolescents will be trained to use Pain Squad+ 
using a standardised procedure. Three repeated audible 
smartphone alerts over a 30 min window will signal each 
adolescent to complete the 8- item pain assessment using 
Pain Squad+ every morning and evening for 8 weeks. 
The timing of morning and evening pain assessments 
will be individualised according to participant’s daily and 
weekly schedules. An automated 30 min window within 
which each assessment must be completed will be set, 
or the assessment will be registered as ‘missed’. Adoles-
cents will also have the option of completing ad hoc pain 
assessments anytime between the automated alert times. 
Algorithm- driven pain self- management advice will be 
issued in response to pain, providing real- time decision 
support (see online supplementary appendix A). One 
hour after a recommendation is made, the app will alert 
adolescents to complete a pain reassessment and addi-
tional advice will be offered as appropriate. All pain assess-
ment and treatment advice data logged will be encrypted 
and wirelessly transferred to a secure server at SickKids 
for storage. Email alerts related to three consecutive 
reports of pain >3/10 will be sent to the study nurse who 
will log into the Analytics Platform to Evaluate Effective 
Engagement (APEEE) platform36 to review the adoles-
cent’s pain report history. The nurse may liaise with the 
adolescent’s healthcare team regarding the case and will 
contact the adolescent within 12 hours of receiving the 
alert, including on weekends. The time of nurse contact 
and the details of the pain treatment conversation will be 
recorded. A research coordinator will provide telephone- 
based technical assistance (weekdays 09:00 to 17:00 EST) 
to participants if required.
Experimental group B
Adolescents randomised to this group will complete pain 
assessments and receive the same smartphone- based 
algorithm- driven pain treatment advice as in Experi-
mental Group A but will not receive nurse- initiated pain 
support.
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Figure 3 Pain Squad+ schedule of enrolment, interventions and assessments. app,application; RN, registered nurse.
Waitlist control group
Adolescents randomised to this group will be waitlisted 
to receive the Experimental Group B condition within 1 
month of completing all post- study outcome measures.
All study groups
Regardless of study group, adolescents will continue to 
receive standard medical care from their treating health-
care teams. All groups will be reminded to pursue help 
using the usual channels (calling oncology clinic, ‘on- 
call’ team or 911) should any medical emergencies arise 
during the study.
outcomes
All outcome measures have demonstrated validity and 
reliability in 12 to 18 year olds with cancer and will be 
assessed according to the schedule shown in figure 3. A 
1 week recall period will be used for all health- related 
outcomes.
Primary outcome
The primary outcome is average pain intensity, measured 
using Brief Pain Inventory (BPI). The BPI assesses 
current pain and ‘worst’, ‘least’ and ‘average’ pain in the 
preceding week using an 11- point numerical rating scale 
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(NRS) with verbal anchors ‘no pain’ at 0 and ‘pain as bad 
as you can imagine’ at 10.37 38 Item scores may also be 
averaged to give a Pain Intensity Summary Score.39
Secondary outcomes
a. Pain interference will be assessed using the Patient 
Reported Outcomes Measurement Information System 
(PROMIS) Pediatric Pain Interference Short- form 
Scale. The PROMIS instrument is a valid 8- item scale 
assessing the impact of pain on function.40 41 Higher 
scores represent greater interference with function.
b. HRQL will be assessed using the Pediatric Quality of 
Life Inventory (PedsQL) 4.0. The PedsQL 4.0 is a valid 
and reliable 23- item instrument not specific to pain.2 42 
It is comprised of 4 subscales (physical functioning, 
emotional functioning, social functioning and school 
functioning), which are summed to provide a total 
score. Higher scores represent better quality of life.
c. Pain management self- efficacy will be assessed with 
Porter’s scale which assesses self- efficacy for managing 
pain, symptoms and function in cancer patients.43 44 
This 16- item scale includes a valid and reliable 5- 
item subscale assessing cancer pain management self- 
efficacy with higher scores indicating more certainty 
and is adapted from a scale that has been successfully 
administered to adolescents.21 45
d. Cost effectiveness and cost utility analyses will determine 
the incremental costs (or savings) of the Pain Squad+ 
app, with and without nurse support, when compared 
with a waitlist control group in reducing pain over 
the study. Quality- adjusted life years will be calculated 
using data from the valid and reliable Health Utility 
Index Mark 2/3 (HUI2/3)46 completed by adoles-
cents. Direct healthcare costs will include the interven-
tion costs as well as costs for health service utilisation 
during the trial. Family out- of- pocket expenses, indi-
rect costs due to lost productivity and health service 
use will be ascertained using standardised customised 
data collection forms completed by caregiver report.
e. Satisfaction with treatment will be assessed using qual-
itative interviews with a subset of participating ado-
lescents. These interviews will specifically be used to 
explore the perceptions of adolescents with cancer 
as they relate to the acceptability (including engage-
ment with pain treatment strategies) of Pain Squad+, 
with and without nurse support or the waitlist control 
condition.
Sociodemographic-related and disease-related data baseline
Adolescent age, sex, ethnicity, school grade, diagnosis, 
stage/risk, relapse- status, treatment- type, date of diag-
nosis, comorbid conditions and medications, pain history; 
as well as caregiver age, sex, ethnicity, educational attain-
ment and financial characteristics; adolescent ownership 
and use of smartphones and adolescent expectation 
about treatment effectiveness (assessed using a valid NRS 
scale with verbal anchors ‘don’t think it will help at all’ at 
0 and ‘think it will help a lot’ at 10).
Participant timeline
An 8- week treatment period will be used (figure 3). The 
primary outcome, and health- related secondary outcomes 
will be assessed at baseline and 2, 4, 8 and 16 weeks post- 
randomisation. Cost- related outcomes will be assessed at 
baseline, 8 and 16 weeks post-randomisation. The primary 
endpoint will be at 4 weeks post- randomisation selected 
as our primary endpoint because, based on our pilot, it is 
feasible to administer the intervention for this period and 
significant pain improvements are observed at 4 weeks.30 
To examine whether duration of Pain Squad+ use changes 
the magnitude or direction of outcome changes, adoles-
cents in the experimental groups will continue to use the 
app until 8 weeks post- randomisation and outcomes will 
be assessed at 2 and 8 weeks (specifically examining the 
effect of shortening or extending intervention use on 
health quality). A longer- term follow- up (16 weeks) will 
be used to examine the maintenance of any Pain Squad+ 
therapeutic gains after discontinuation of the interven-
tion. Qualitative interviews will be conducted at study 
completion or withdrawal.
sample size
The sample size is calculated based on detecting a differ-
ence of 1.1 points between any two treatment groups in 
the primary outcome, average pain intensity reported 
on the BPI, at 4 weeks post- randomisation. This differ-
ence in pain intensity represents one of minimal clin-
ical significance (the smallest difference that patients 
perceive as beneficial) for pain intensity improvement on 
a 0 to 10 scale in adolescents.47 Our pilot study showed 
that the effect size for a 1.1- point change in pain inten-
sity in adolescents following Pain Squad+ was 0.52.30 We 
have used a conservative approach which accounts for the 
1- group design of our pilot and have powered this RCT 
to detect a primary outcome effect size of 0.5. Using a 
sample size calculation for analysis of covariance models 
and controlling for baseline pain intensity,48 sample sizes 
of 63 per group, or 189 in total, will be required to achieve 
80% power to detect an effect size of 0.5 between any two 
treatment groups. This calculation assumes an overall 
Type I error set at 0.05 allowing for Bonferroni- corrected 
pairwise comparisons of treatment arms, and a conserva-
tive correlation between baseline and follow- up measure-
ments of 0.5. To account for the 5% drop out and 10% 
loss to follow- up rates observed in the pilot study,30 we will 
recruit 222 (ie, 189/0.85) adolescents into the study, or 
74 per group.
recruitment
Each site research assistant (RA) will coordinate with the 
clinic healthcare team to determine eligibility. Identified 
eligible potential participants will be recruited via tele-
phone call (following a mailed or emailed study informa-
tion letter) or in- person at the hospital. Recruitment will 
begin in November 2019 and is projected to end in April 
2022.
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Allocation and blinding
A centrally controlled, online randomisation service will 
be used to assign adolescent to each study group using a 
1:1:1 allocation model. When an adolescent is ready to be 
randomised, the lead site RA will enter a unique identi-
fication number and information about the stratification 
variable (recruitment site) into the online programme. 
Group allocation will be assigned with block sizes of 6 and 
9 within each stratum. The RA, who has no role in allo-
cation sequence generation, will then inform the adoles-
cent of their group assignment and instruct them on the 
procedures to be followed. The investigators, including 
data analysts, will be blind to group allocation. Treatment 
allocation may be unblinded only by the principal inves-
tigators when knowledge of the actual treatment is essen-
tial for further treatment of the patient,49 as determined 
by the adolescent’s treating oncologist.
data collection methods
Pre-randomisation procedures
Eligible adolescents who are hospital inpatients or have 
a scheduled clinical appointment during the recruit-
ment period will be invited to participate. Site RAs will 
obtain informed consent from adolescents and one of 
their primary caregivers. The research coordinator will 
track the number of eligible adolescents approached and 
reasons for refusal on an investigator- developed form. 
The lead site RA will obtain baseline data on adolescents 
(sociodemographic- related and disease- related character-
istics) from their medical records and administer online 
pre- intervention measures on the secure password- 
protected Research Electronic Data Capture (REDCap) 
site.
Post-randomisation procedures
At 2, 4, 8 and 16 weeks post- randomisation, the lead site RA 
will contact adolescents and caregivers up to three times 
by text message, email and/or telephone and ask them 
to complete all outcome measures. To do so, participants 
will log into REDCap using an Internet- enabled device 
and their unique identifier. Outcome measure data will be 
time- stamped by REDCap when entered and participants 
will be encouraged to complete measures immediately 
after contact with the RA. The RA will provide telephone 
troubleshooting in the case of REDCap or questionnaire 
problems. Adolescents will receive a gift certificate for 
each outcome assessment completed in recognition of 
their time and effort. Loaned phones will be returned. 
All data will be exported from REDCap to SAS statistics50 
on the secure server at SickKids for analysis. Qualitative 
interviews will be conducted with a subset of adolescents 
from each trial arm. Adolescents who vary across age, sex, 
diagnosis and study engagement will be recruited. Inter-
views will be conducted until data saturation (ie, no new 
data generated in an interview). We anticipate conducting 
a total of 45 interviews. A semi- structured interview guide 
that is based on the guide used in our pilot25–31 and has 
been refined by former adolescent cancer patients will 
be used. Interviews will be audio- recorded and may be 
conducted in- person or over the telephone. Field notes 
will be taken by the interviewer.
data management and confidentiality
All outcome data will be collected online using REDCap 
and the associated database will be regularly backed up 
by SickKids. All data files (including backups) will be kept 
in a secured environment in Canada and are available for 
recovery. The secure digital platform APEEE will be used 
to collect adolescent- entered pain assessment and treat-
ment data, as well as data related to app engagement, for 
each of the intervention groups. Data will be accessible 
only by the study team and staff. Any hardcopy docu-
mentation (eg, consent forms) will be stored in locked 
cabinets in locked offices at study sites, separate from the 
stored data. All staff will be provided with training on the 




Pain intensity, pain interference, HRQL and self- efficacy 
data will be analysed using an intent- to- treat approach.51 
Background variable data collected at baseline will be 
described using measures of central tendency and vari-
ance. If outcome data meet the requirements for para-
metric statistics (eg, approximate normality, linear 
distribution), linear mixed models will be used to 
assess the effects of the intervention on primary and 
secondary outcomes with baseline scores used as covari-
ates. Regarding our HRQL outcome, as with our pilot, we 
will separately analyse the physical, emotional, social and 
school subscales of the PedsQL, as well as the total scale 
score. To explore the effects of demographic, disease- 
related variables and pain treatment strategies used on 
outcomes, separate linear mixed models with these vari-
ables as covariates will be used. A significance level of 0.05 
will be used for all outcomes (with adjustment made for 
serial analyses).
Economic analyses
Cost effectiveness and cost utility analyses will be 
conducted using both a health system and societal 
perspective. Cost effectiveness and cost utility will 
be expressed as incremental cost effectiveness ratios 
(ICERs), calculated by dividing the incremental costs 
between treatment arms by the incremental difference 
in average pain intensity or the incremental change in 
utility scores, measured by the HUI2/3. Multiple ICERs 
will be calculated comparing each of the three study 
groups in a pairwise fashion for both the cost effective-
ness and cost utility analyses. Deterministic and probabi-
listic sensitivity analysis will be performed to evaluate the 
robustness of the results. A 95% CI for incremental costs, 
incremental effects and the ICER will be calculated from 
study data.









pen: first published as 10.1136/bm





8 Jibb L, et al. BMJ Open 2020;10:e037251. doi:10.1136/bmjopen-2020-037251
Open access 
Qualitative interview analyses
Audio- recorded interviews will be transcribed verbatim. 
Transcribed data will be managed using NVivo 12.0 soft-
ware (QRS International). Data analysis will occur shortly 
after each interview is conducted so that identified issues 
can be used to inform subsequent interview content. Data 
will be read several times by the study team for overall 
understanding and to identify data codes. Data will then 
be coded using a line- by- line approach according to study 
objective. Codes will be grouped into categories based on 
between- code relationships. Category development will 
occur until all data can be classified under the existing 
categories. Categories will then be grouped into themes. 
Field notes and relevant sociodemographic and disease 
characteristics will be integrated into the analysis process 
to illustrate or clarify emerging categories and themes.
Patient and public involvement statement
Adolescents with cancer have been directly and actively 
involved in all stages of the development and evaluation 
of the Pain Squad+ app, including determining the feasi-
bility of this study, evaluating any potential burden on 
adolescent participants and in the development of this 
research protocol. An adolescent with cancer advisory 
committee has been established to guide trial conduct 
and results interpretation and dissemination from a 
patient perspective and will report to the principal inves-
tigators. This advisory committee will meet regularly with 
the lead investigators to ensure the trial is guided by the 
priorities and experiences of adolescents with cancer.
EthICs And dIssEMInAtIon
trial steering and data safety and monitoring committees
The trial steering committee consists of the lead study 
team. Virtual progress meetings with all steering 
committee members will be routinely collected to ensure 
the smooth running of the study. A datasafety and moni-
toring committee (DSMC) guided by a prepared charter 
of roles and responsibilities (available from corresponding 
author) and consisting of a statistical expert, a paediatric 
oncology nurse scientist and a paediatric anaesthesiolo-
gist who are independent of the research team has been 
established. The DSMC will meet biannually to review 
recruitment, accumulating study data and adverse events 
and will provide guidance to the study team regarding 
any needed action.
safety appraisal and protocol amendment reporting
Based on our pilot and similar studies conducted by our 
group,12 there are no known risks to adolescents enrolled 
in the experimental or control groups. Any adverse 
events reported by adolescents, their healthcare teams or 
the study nurse will be tracked on a critical incident form 
and reported to treating oncologists as soon as possible. 
Site ethics boards and the DSMC will also be contacted 
as soon as possible after the occurrence of any adverse 
event. Any major amendments to the protocol that may 
impact the conduct of the study or participant benefits or 
harms will be agreed on by the trial steering committee, 
as well as the adolescent with cancer advisory committee 
and approved by all site ethics boards before they are 
instituted. These amendments will also be communicated 
with study participants as soon as possible by site RAs.
dissemination and knowledge translation plan
We have and will continue to involve patient, healthcare 
professional, policymaking and research stakeholders in 
all stages of the research process. We will present research 
findings at international oncology and paediatric confer-
ences and publish in leading journals. Our knowledge 
translation strategy will also include: a one- page brochure 
for distribution to oncology healthcare professionals, 
a~3 min video for adolescents with cancer, which will be 
posted on websites such as YouTube, media releases (ie, 
for newspaper, magazines), posting on partner organ-
isation, hospital and university websites and supporting 
adolescents and caregivers in translating results into fact 
sheets to support these key stakeholders in educating 
their healthcare professionals about results (ie, consumer 
detailing).
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